Vascular-targeted photodynamic therapy with BF2-chelated Tetraaryl-Azadipyrromethene agents: a multi-modality molecular imaging approach to therapeutic assessment.
AuthorsByrne, A T
O'Connor, A E
Curran, K M
Rousseau, J A
Callanan, J J
O'Shea, D F
Gallagher, W M
AffiliationUCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland.
Cell Line, Tumor
Magnetic Resonance Imaging
Mammary Neoplasms, Experimental
Mice, Inbred C57BL
MetadataShow full item record
CitationVascular-targeted photodynamic therapy with BF2-chelated Tetraaryl-Azadipyrromethene agents: a multi-modality molecular imaging approach to therapeutic assessment. 2009, 101 (9):1565-73 Br. J. Cancer
JournalBritish journal of cancer
AbstractPhotodynamic therapy (PDT) is a treatment modality for a range of diseases including cancer. The BF(2)-chelated tetraaryl-azadipyrromethenes (ADPMs) are an emerging class of non-porphyrin PDT agent, which have previously shown excellent photochemical and photophysical properties for therapeutic application. Herein, in vivo efficacy and mechanism of action studies have been completed for the lead agent, ADMP06.
A multi-modality imaging approach was employed to assess efficacy of treatment, as well as probe the mechanism of action of ADPM06-mediated PDT.
Tumour ablation in 71% of animals bearing mammary tumours was achieved after delivery of 2 mg kg(-1) of ADPM06 followed immediately by light irradiation with 150 J cm(-2). The inherent fluorescence of ADPM06 was utilised to monitor organ biodistribution patterns, with fluorescence reaching baseline levels in all organs within 24 h. Mechanism of action studies were carried out using dynamic positron emission tomography and magnetic resonance imaging techniques, which, when taken together, indicated a decrease in tumour vascular perfusion and concomitant reduction in tumour metabolism over time after treatment.
The encouraging treatment responses in vivo and vascular-targeting mechanism of action continue to indicate therapeutic benefit for this new class of photosensitiser.
- Mechanism of cell death mediated by a BF2-chelated tetraaryl-azadipyrromethene photodynamic therapeutic: dissection of the apoptotic pathway in vitro and in vivo.
- Authors: O'Connor AE, Mc Gee MM, Likar Y, Ponomarev V, Callanan JJ, O'shea DF, Byrne AT, Gallagher WM
- Issue date: 2012 Feb 1
- Effective treatment of chemoresistant breast cancer in vitro and in vivo by a factor VII-targeted photodynamic therapy.
- Authors: Duanmu J, Cheng J, Xu J, Booth CJ, Hu Z
- Issue date: 2011 Apr 26
- The synthesis of 64Cu-chelated porphyrin photosensitizers and their tumor-targeting peptide conjugates for the evaluation of target cell uptake and PET image-based pharmacokinetics of targeted photodynamic therapy agents.
- Authors: Mukai H, Wada Y, Watanabe Y
- Issue date: 2013 Aug
- Fluorescence and photodynamic effects of bacteriochlorin a observed in vivo in 'sandwich' observation chambers.
- Authors: van Leengoed HL, Schuitmaker JJ, van der Veen N, Dubbelman TM, Star WM
- Issue date: 1993 May
- Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma.
- Authors: Ferrario A, von Tiehl KF, Rucker N, Schwarz MA, Gill PS, Gomer CJ
- Issue date: 2000 Aug 1